Due to the specific role of IL-1 on the immune system, therapy to inhibit IL-1 function has emerged as a potential therapeutic target to weaken inflammation in CKD patients, especially in HD patients (Barreto et al., 2010; Ridker et al., 2018; Düsing et al., 2021). Here, IL1B is linked to Huntington disease.